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Doxorubicin (DOX) is an important tumor chemotherapeutic agent, acting mainly by geno-
toxic action. This work focus on cell processes that help cell survival, after DOX-induced
DNA damage. In fact, cells deﬁcient for XPA or DNA polymerase eta (pol eta, XPV) proteins
(involved in distinct DNA repair pathways) are highly DOX-sensitive. Moreover, LY294002,
an inhibitor of PIKK kinases, showed a synergistic killing effect in cells deﬁcient in these
proteins, with a strong induction of G2/M cell cycle arrest. Taken together, these results
indicate that XPA and pol eta proteins participate in cell resistance to DOX-treatment,
and kinase inhibitors can selectively enhance its killing effects, probably reducing the cell
ability to recover from breaks induced in DNA.
 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
Over the past 40 years or more, Doxorubicin (DOX)
(tradename, Adriamycin), an anthracycline antibiotic,
has been widely used in the chemotherapeutic treatment
of a broad range of malignancies, from solid tumors, as
those in the breast, liver and bile ducts, to hemaetological
diseases, such as non-Hodgkin’s lymphoma. Nevertheless,
despite its extensive clinical use, DOX mechanisms of ac-
tion are, as yet, not fully understood. The most well charac-
terized mechanism is through the inhibition of the enzyme
topoisomerase-II (topo-II), with the subsequent formationrestes, 1374, Edifício
, SP, Brazil. Tel.: +55
k).
nder the Elsevier OA license.of double-strand breaks (DSBs) in DNA. However, several
othermechanisms are also thought to play a role in DOX in-
duced cytotoxicity, such as DNA adduct formation, DNA
cross-linking and free radical formation. Furthermore,
DOX-genotoxicity is also affected by both drug concentra-
tion and cell type speciﬁcity [1]. Apart from the uncertainty
regarding DOX-induced DNA lesions, the mechanisms in-
volved in their repair are also poorly understood. Deducing
how these lesions are repaired is a current challenge that, if
successful, could lead to more favorable clinical outcomes
for patients undergoing DOX-treatment.
It has been shown that the kinase DNA-PKcs, a compo-
nent of the Non-Homologous End Joining (NHEJ) pathway,
participates in the repair of DOX-induced DNA lesions,most
likely by repairing the DSBs induced by the inhibition of
topo-II [2]. Another pathway that seems to be relevant in
their repair is Nucleotide Excision Repair (NER), one of the
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there are two subpathways that differ only in the recogni-
tion of DNA damage, viz., transcription coupled repair
(TCR),which is selective for lesions in the transcribed strand
of expressed genes, and global genome repair (GGR), that
acts throughout the entire genome. After DNA damage rec-
ognition (in GGR by the proteins XPC-hHR23B and DDB1/
DDB2), the helicases XPB and XPD sequentially open the
double helix, and the endonucleases XPG and ERCC1-XPF
cleave the damaged strand a few bases away from the le-
sion. The proteins XPA and RPA are also important for the
efﬁcacy of this repair process, which is followed by the re-
moval of the DNA segment containing the lesion, and the
subsequent resynthesis of this strand, using the intact one
as template. Defects in the NER proteins XPA–XPG give rise
to the inherited disease xeroderma pigmentosum (XP) [3,4].
When NER is not impaired, a variant form of this disease
(XPV) can also be caused by defects in post replication re-
pair machinery, or more speciﬁcally, defects in the protein
DNA polymerase eta (pol eta) involved in translesion syn-
thesis of DNA (TLS) [5]. Cells derived from XP patients and
defective in the proteins XPA, XPC [6] and XPD [7] are more
sensitive to the treatment with DOX, suggesting a role for
these proteins in the repair of DOX-induced lesions.
In order to better understand the involvement of XP pro-
teins in the repair of DOX-induced lesions, human cells
defective in theproteinsXPA,XPF or pol eta (XPV)were trea-
ted with clinical doses of DOX [1], whereupon their re-
sponses to the drug were analyzed. As shown here, cells
defective in XPA (XP12BE) or pol eta (XP30RO) are muchFig. 1. DNA repair deﬁcient and proﬁcient cell sensitivity to DOX. Cells were exp
fraction was detected by ﬂow cytometry (A), or cell viability assessed by XTT ass
C5RO, XP12BE (XPA), XP30RO (XPV) and XP51RO (XPF). Statistical analysis was
repair deﬁcient (XP12BE, XP30RO and XP51RO) cells. ⁄⁄ Signiﬁcantly different
⁄⁄⁄P < 0.001.more sensitive to DOX than cells either deﬁcient in XPF
(XP51RO) or proﬁcient in DNA repair (MRC5). Cell response
was also evaluated after treatment with both DOX and
LY294002, an inhibitor of PIKKs, such as DNA-PKcs [8,9]. It
was noted that LY294002 potentiates the cytotoxic effect
of DOX only in the repair-deﬁcient cells XP12BE and
XP30RO, but not in the wild type MRC5. Moreover, in all
the cells used in this study, DOX treatment induced a
G2/M arrest in the cell cycle, also enhanced by LY294002.
2. Materials and methods
2.1. Cell culture conditions
The cells used were: SV40-transformed human ﬁbro-
blasts derived from skin biopsies of XP patients of comple-
mentation groups A (XPA–XP12BE and XP12RO cells) and
V (XPV–XP30RO cells); SV40 transformed human ﬁbro-
blasts derived from lung tissue of a normal fetus (MRC5
cells); hTERT transformed human ﬁbroblasts derived from
skin biopsies of an XP patient of complementation group F
(XPF–XP51RO), and those from a normal individual
(C5RO). XP51RO and C5RO were kindly provided by Dr. N.
Jaspers (Erasmus University, Netherlands). MRC5 and
C5RO cells with normal levels of DNA repair were used as
controls. Cells were routinely grown at 37 C in a 5% CO2
humidiﬁed atmosphere in the appropriate medium: MRC5,
XP12RO and XP12BE in Dulbecco’s modiﬁed Eagle medium
(DMEM–Invitrogen, Life Technologies, California, USA),
supplemented with 10% fetal bovine serum (FBS – Cultilab,osed to the indicated doses of DOX for 48 h, whereupon either the sub-G1
ay (B). The cell lines used in these experiments were, as indicated: MRC5,
applied for comparing DNA repair proﬁcient (MRC5 and C5RO) with DNA
P < 0.01 for XP12BE versus MRC5, and P < 0.05 for XP30RO versus MRC5;
Fig. 2. DOX-induced cell death. Cells were exposed to the indicated doses of DOX for 48 h, and then analyzed with a combination of ﬂuorescent dyes. A
combination of ﬂuorescein di-acetate (FDA), propidium iodide (PI) and Hoechst (HO) dyes was used to distinguish viable cells from those in necrosis, or
early or late apoptosis. Cells were counted, and the percentages plotted on a graph. The cell lines used were: MRC5, XP12BE (XPA) and XP30RO (XPV).
Statistical analysis, by cell line, was applied for comparing DOX-treated cells with non-treated. ⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001.
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medium (MEM – Invitrogen, Life Technologies), supple-
mentedwith10%FBS; andXP51ROandC5RO inHAM’smed-
ium (Invitrogen, Life Technologies), supplementedwith 15%
FBS.
2.2. Treatment conditions
For cytotoxicity assays, cells, in the appropriate med-
ium, were ﬁrst seeded onto 6-well plates at a concentra-
tion of 6  104 cells per well, and then grown for 24 h
prior to treatment. The cultures were treated, in the dark,
with different concentrations of DOX (up to 200 ng/mL)
for 24, 48 or 72 h, as indicated. As control, cells were incu-
bated with 0.25% ethanol for the same period of time. For
co-treatments with DOX and LY294002 (modiﬁed from
[8,9]), cells were incubated with 10 lM LY294002, 1 h
prior to addition of DOX to the culture medium. As control,
cells were incubated with 0.1% DMSO.
2.3. Cell viability
After each treatment, cell viability was assessed with a
Cell Proliferation Kit II (XTT) (Roche, Basel, Switzerland),
according to manufacturer’s instructions. Brieﬂy, after dis-
carding the medium, 1 mL of XTT labeling mixture was
added to the cells and incubated for approximately 2 h at37 C. Absorbance was measured at 492 nm (A492) and
750 nm (A750), the ﬁnal result corresponding to A492–A750.
2.4. Flow cytometry analysis (sub-G1 assay, cell cycle and
cH2AX analysis)
After treatment, adherent cells were trypsinized and
mixedwith detached dying cells, washedwith PBS and then
ﬁxed with chilled 70% ethanol for at least 24 h at 20 C.
Staining was performed at room temperature for 30 min in
ﬁltered PBS containing 20 lg/mL propidium iodide (PI),
200 lg/mL RNase A and 0.1% Triton X-100. Data were col-
lectedwith a Guava Flow Cytometer (GE Healthcare, United
Kingdom), and the percentage of sub-G1 population deter-
minedwithCytoSoftDataAcquisitionandAnalysis Software
(GE Healthcare). For cell cycle, the collected data was ana-
lyzed with ‘‘ModFit LT’’ Software (Verity Software House,
Maine, USA). For cH2AX immunostaining, cells were ﬁxed
with 1% formaldehyde and then 70% ethanol. After blocking
andpermeabilization (0.2% TritonX-100 in PBS and1%BSA),
cells were incubated with the antibody anti-cH2AX (Anti-
phospho-Histone H2A.X (Ser139), clone JBW301 from Up-
state, Millipore) diluted 1:500 for 1 h at room temperature.
Cells were then washed and incubated with a secondary
antibody (anti-mouse FITC, from Sigma) at 1:200 for 1 h at
room temperature in the dark. Before collecting data, cells
were stained with PI solution, as described above.
Fig. 3. Real time analysis of DOX-induced cytotoxicity. Histograms were obtained using the xCELLigence System. Cells were grown for 24 h before initiating
DOX treatment (arrows), at the indicated doses (12.5 or 100 ng/mL; DOX 0 indicates the controls, incubated only with 0.25% ethanol). Cell index (CI) was
recorded every hour, except for the ﬁrst 48 h immediately after initiation of treatment, when recordings were every 15 min. The results are the means of at
least three replicates, with displayed standard error bars.
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ﬂuorescence staining
Following treatment, adherent and detached cells were
harvested by centrifugation, whereupon pellets were sus-
pended in 20 lL of chilled PBS. In order to distinguish
apoptotic and necrotic cells from those viable, the cellular
suspension was mixed with a combination of dyes, viz.,
705 lg/mL ﬂuorescein di-acetate (FDA), 250 lg/mL PI,
and 100 lg/mL Hoechst 33342 (HO). FDA and HO are vital
dyes, which stain the cytoplasm and nucleus of viable cells,
respectively. The necrotic and late stage of apoptotic cells
are identiﬁed by PI staining. Whereas the characteristicpattern of chromatin fragmentation was noted in cells in
the early (viable-HO stained) and late (dead-PI stained)
phases of apoptosis, the nucleus was non-fragmented in
normal and necrotic cells [10]. At least 500 cells were ran-
domly scored by microscopic analysis.
2.6. Real-time cellular cytotoxicity assay (xCELLigence)
Assaying was according to manufacturer’s instructions
and as previously described [11–14]. Brieﬂy, cells were
seeded onto a 96-well E-Plate (Roche), with interdigitated
microelectrodes at the bottom of each well, at a concentra-
tion of 1.2  104 (MRC5), 3.1  103 (XP12BE) or
Fig. 4. LY294002 enhances the DOX cytotoxic effect. Cells were exposed to DOX (10 ng/mL and 50 ng/mL) and/or 10 lM LY294002 (LY). The sub-G1 fraction
was detected by ﬂow cytometry, at the indicated times after treatment. The cell lines used in these experiments were, as indicated: MRC5, XP12BE (XPA)
and XP30RO (XPV). Statistical analysis, by cell line, was applied for comparing cells treated only with DOX with those co-treated with both DOX and LY.
⁄P < 0.05; ⁄⁄⁄P < 0.001.
112 M.C.S. Moraes et al. / Cancer Letters 314 (2012) 108–1186.2  103 (XP30RO) cells per well. After 30 min at room
temperature, the E-Plate was placed onto an xCELLigence
Real-Time Cell Analyzer (RTCA) SP System device (Roche),
located inside a tissue culture incubator, where cells were
left to grow for 24 h before being exposed to 0.25% ethanol
or various doses of DOX (from 6.25 ng/mL to 200 ng/mL).
Impedance was continuously measured over the following
72 h. The increase in the number and size of cells attached
to the electrode sensors leads to increased impedance, from
which derive the cell index values displayed at the plot.
Hence, the cell index correlates with the number of cells at-
tached to the bottom of the well.
2.7. Statistical analysis
Results represent the mean of two or three independent
experiments, each done in triplicate, with error bars show-
ing the standard error. Experimental differences were
tested for signiﬁcance using Two-way ANOVA analysis, fol-
lowed by Bonferroni post-testing (Prism 5 – GraphPad
Software Inc., California, USA).
3. Results
3.1. DOX-induced cytotoxicity
In order to deﬁne DOX-induced cytotoxicity in cells proﬁcient (MRC5
and C5RO) and deﬁcient (XP12BE, XP30RO and XP51RO) in DNA repair,
cell viability and cell death induced by this chemotherapeutic drug were
determined. Cells deﬁcient in XPA (XP12BE) or in pol eta (XP30RO)
proved to be more sensitive to 48-h treatments with clinical doses ofDOX than those deﬁcient in XPF (XP51RO) or the wild type (Fig. 1). Be-
sides dying more from apoptosis, as inferred from increased percentages
of fragmented DNA (sub-G1 fraction) (Fig. 1A), XP12BE and XP30RO cells
are also less viable than MRC5 (Fig. 1B). XP12RO, another XPA-deﬁcient
cell line with similar higher sensitivity to DOX (data not shown; and
[6]), was used for corroborating the results with XP12BE. Interestingly,
XP51RO cells are not more sensitive to DOX, at least not with the doses
used, as shown by sub-G1 levels (Fig. 1A). This absence of an observable
phenotype could be attributed to residual NER activity retained in cells
derived from XPF patients, which can sometimes reach 30% of normal
NER levels [15]. Thus, it stands to reason that this residual activity could
be responsible for the repair of DNA damage induced by the doses used
herein. Moreover, as XPF, an endonuclease, is also involved in homolo-
gous recombination repair of mainly DNA interstrand crosslinks, the re-
sults indicated that either this repair pathway is not directly involved
in the repair of DOX-induced DNA lesions, or other alternative endonucle-
ases are. Interestingly, in these and the following experiments, XP-A cells
showed to be more sensitive than XP-V cells. This may indicate that full
deﬁciency of NER is more deleterious than the lack of pol eta, probably
compensated by the repair of lesions by NER in XP-V cells.
To check whether DOX induces death by necrosis and conﬁrm the in-
crease in apoptosis observed earlier, treated and non-treated cells were
stained with dyes that allow distinguishing normal viable cells, necrotic
cells and cells in early or late apoptosis. As shown in Fig. 2, treatment
with low doses of DOX for 48 h induced apoptosis in both XP12BE and
XP30RO cells, but not in MRC5, thus conﬁrming the results obtained by
sub-G1 cellular fraction analysis (Fig. 1A). Although there was a slight in-
crease in necrosis in XP12BE cells, this was not so in either XP30RO or
MRC5 cells. Even though statistically signiﬁcant, the occurrence was more
likely due to experimental variation, since in another set of independent
experiments no such increase was detected (Fig. 5).
In order to analyze DOX-induced cellular cytotoxicity in real time,
thereby complementing the end-point assays already described, the
xCELLigence RTCA SP System (Roche), which does not depend upon the
incorporation of labels [11–14], was used. As can be seen in Fig. 3,
Fig. 5. Cell death induced by DOX and LY. Cells were exposed to DOX (XP12BE: 10 ng/mL; MRC5 and XP30RO: 50 ng/mL) and/or 10 lM LY, as indicated. A
combination of FDA, PI and HO dyes was used to distinguish cells in early or late apoptosis from viable or necrotic cells. The cell lines used were: MRC5,
XP12BE (XPA) and XP30RO (XPV). Statistical analysis, by cell line, was applied for comparing control non-treated cells with cells treated as indicated.
⁄P < 0.05; ⁄⁄⁄P < 0.001.
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(100 ng/mL), whereas MRC5 cells presented no cytotoxicity. Conﬁrming
previous results, at lower doses (12.5 ng/mL) only XP12BE manifested
DOX-induced cytotoxic effects.
Thus, it is inferred that the active involvement of XPA and pol eta pro-
teins in the efﬁcient repair of lesions caused by clinical doses of DOX is
essential for cell survival.3.2. LY294002 potentiates the cytotoxic effects of DOX in repair-deﬁcient cells
In some tumor cells, the cytotoxic effects of DOX are enhanced by
LY294002 [8,9], an inhibitor of phosphatidylinositol-3-kinases (PI3Ks)
and related protein kinases (PIKKs) [16–20]. Since kinases involved in
DNA damage response and repair, such as ATM, ATR and DNA-PKcs, are
members of the PIKK family [21,22], it was decided to analyze the effects
of co-treatment with DOX and LY294002 (LY) in XP12BE and XP30RO re-
pair-deﬁcient cells. As shown in Fig. 4, DOX-cytotoxic effects were cer-
tainly enhanced in both, since co-treatment lead to increased levels of
apoptosis. As to repair-proﬁcient MRC5 cells, the addition of LY induced
no like effect. Moreover, it was noted that, although the sensitivity proﬁle
in XP30RO is the same as in XP12BE, the response of the former to both
treatments (DOX alone, and DOX plus LY) was delayed.
In order to further establish the additive cytotoxic effect of LY in DNA
repair-deﬁcient cells treated with DOX, staining experiments similar to
those shown in Fig. 2 were carried out. A lower dose (10 ng/mL) of DOX
was used for the treatment of XP12BE cells, seeing that at higher doses,
the levels of DOX-induced death were already so high in the 48-h treat-
ment (see Fig. 4), that it would impair the detection of any potential
LY-induced increase. Again, LY strongly enhanced the effects of DOX only
in XP12BE and XP30RO cells, as shown by an increase in the percentage of
apoptotic cells in both when compared to treatments with DOX or LY
alone. In MRC5 cells, there was no increase in cell death (Fig. 5).Thus, deﬁciencies in repair processes mediated by XPA and pol eta
could possibly contribute to the DOX/LY synergistic cytotoxic effects ob-
served, as the proper activity of these proteins is related to cellular resis-
tance to this co-treatment.
3.3. Effects of DOX in the cell cycle
In several cell lines, DOX-treatment leads to cell cycle arrest, mainly
in the G2/M phases [7,23,24]. As there is no mention in the literature of
this in cells deﬁcient in either XPA or pol eta, DOX-effects throughout
the cell cycle progression in XP12BE, XP30RO and MRC5 cells were ana-
lyzed. Direct analysis of the cycle in treated and nontreated cells demon-
strated that DOX induces G2/M arrest in MRC5, XP12BE and XP30RO cell
lines, as can be observed in representative histograms (Fig. 6A) and quan-
titative data (Fig. 6B). It was also shown that in co-treatments DOX plus
LY, the arrest was more pronounced than in treatments with DOX alone.
However, treatment with LY alone was not cell cycle-arrest inductive
(Fig. 6). After co-treatment, G2/M arrest in MRC5 cells seemed to be even
more pronounced than in both XP12BE and XP30RO (Fig. 6), even though
prolonged treatment or treatment with higher doses of DOX eventually
lead to the same phenotype (data not shown). This is probably due to
MRC5 cell proﬁciency in DNA repair, which would allow for more efﬁcient
activation of the appropriated checkpoint, hence blocking more rapidly
the cell cycle and giving rise to less cell death.
Thus, after treatmentwith DOX, cell cycle progression response is basi-
cally similar in cells proﬁcient (MRC5) and deﬁcient (XP12BE and XP30RO)
in DNA repair, since arrest of the cell cycle in G2/M was evident in all the
three. Furthermore, growth arrest was also enhanced by LY294002.
3.4. Quantiﬁcation of cH2AX in DOX-treated cells
DOX is considered a topo-II poison, and the blockage of DNA replica-
tion by this drug may lead to the formation of DSBs. In fact, cells treated
with DOX show the induction of DSBs, as determined by the phosphory-
Fig. 6. DOX-induced G2/M cell cycle arrest. Cells were exposed to 10 ng/mL DOX and/or 10 lM LY for 48 h, whereupon the cell cycle of treated and non-
treated cells were analyzed with ‘‘ModFiT’’ software. Representative histograms are shown in (A), and the quantiﬁed results in (B). The cell lines used were:
MRC5, XP12BE (XPA) and XP30RO (XPV). Statistical analysis, by cell line, was applied for comparing control non-treated cells with treated cells (⁄), or cells
treated only with DOX with cells submitted to DOX-plus-LY co-treatment (#). ⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001.
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responsible for chromatin remodeling at the region of DSBs, opening ac-
cess of DNA repair machineries to these lesions. Although, one would
not expect a participation of NER in the repair of DSBs, DNA pol eta could
well be involved in protection from these types of lesion. The induction of
cH2AX in treated cells was immunologically detected, through the cell
cycle, by ﬂow cytometry. The results, summarized in Fig. 7, indicate that
continuous treatment of cells with low concentrations (10 ng/mL) of DOX
leads to increased induction of cH2AX-labeled cells, at least up to 48 h.
For higher doses of DOX (50 ng/mL, for 24 h) it seems that most of the liv-
ing cells appear to be labeled. Curiously, there is no clear difference on the
induction of cH2AX (in living cells) when the three cell lines are com-
pared, although the increased induction of cell death (sub-G1) in treated
XP-A and XP-V cells is conﬁrmed. This indicates that XPA and pol eta arenot involved in the processing of DSBs. However, when the inhibitor LY is
added to the cells, there is a tendency to increase the frequency of
cH2AX-labeled cells, indicating that the kinases targeted by LY may con-
tribute to a reduction in these lesions, and also that kinase inhibition does
not reduce phosphorylation of H2AX. Moreover, the labeled cells seem to
be distributed in the different cell cycle phases, with a strong labeling of
G2 cells, which seem to be arrested in G2/M, as commented above.
4. Discussion
DOX is one of themost commonly used chemotherapeu-
tic drugs, with a wide range of activity against solid tumors,
lymphomas and leukemias. Even though classiﬁed as a
Fig. 7. Quantiﬁcation, by immunodetection, of cH2AX after DOX-treatment. Cells were exposed to DOX (10 ng/mL) and/or 10 lM LY for the indicated
periods of time (A), or to 50 ng/mL and/or LY for 24 h, as indicated. Cell cycle (PI) and cH2AX formation were detected by ﬂow cytometry. Results obtained
only with DOX (10 ng/mL) are illustrated in (A), where cH2AX formation is presented as a function of cell cycle phase (sub-G1, G1, S and G2 – indicated
below the graphs). The quantiﬁcation shown in (B) was performed only considering living cells (not considering sub-G1 cells), independently of the cell
cycle phase.
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been described, which relevance for speciﬁc clinical antitu-
moral effects remains controversial. DOX activity can gen-
erate many types of DNA damage, including DSBs, DNA
cross-linking, DNA adducts and damage induced by free
radical formation [1,25–30]. However, little is known aboutthe mechanisms and proteins involved in their repair.
Recently, Safﬁ and colleagues demonstrated that the heli-
case XPD, a member of the NER pathway, is involved in
the repair of DOX-induced lesions, as XPD-deﬁcient cells
are more sensitive to treatments with DOX [7]. This is con-
trary to a previous report showing that rodent cells deﬁcient
Fig. 8. Scheme indicating potential DNA repair pathways involved in DOX-induced DNA damage. Mechanisms for the induction of DNA damage by DOX are
indicated by blue arrows, while DNA repair and damage response pathways are indicated in green arrows. The proteins represented within circles provide
potential targets to potentiate the chemotherapy effects of DOX to induce tumor cell killing (only those discussed in the text are shown). (For interpretation
of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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adducts [31]. The fact that, in the latter case, rodent cells
(instead of human cells) were treated with DOX for only
4 h [31], might account for differences between the two re-
ports. There is also evidence that XPA, XPC [6], DNA-PKcs [2]
and ATM [27] are somehow involved in repairing these le-
sions. In order to better understand how DOX-induced
DNA lesions are processed, the response of cells proﬁcient
and deﬁcient in DNA repair to treatments with DOX was
investigated.
Previously, DOX-induced DNA damage was identiﬁed
through comet assays [6,7]. Herein, it is shown that both
XPA and pol eta are necessary for the effective repair of
DNA lesions induced by clinical doses of DOX, since cells
deﬁcient in these proteins are more sensitive to the cyto-
toxic effects of DOX treatment than MRC5 cells, which
are proﬁcient in DNA repair mechanisms (Figs. 1–3). On
the other hand, the absence of the endonuclease XPF does
not render cells more sensitive to clinical doses of DOX
(Fig. 1). Since the importance of NER in the repair of
DOX-induced lesions has been shown, it is possible that
the residual NER activity normally observed in XPF cell
lines is sufﬁcient to avoid cell death [15], as compared to
XPA cells that are >95% DNA repair deﬁcient. In addition,
cell cycle analysis demonstrated that DOX induces G2/M
arrest in all the cell lines (Fig. 6). Whereas XPA is a member
of the NER pathway, pol eta is traditionally considered to
be a member of the TLS pathway, which bypasses unre-
paired lesions by way of a series of error-prone translesion
DNA polymerases [3,32]. Nevertheless, it has been shown
that pol eta also participates in the process of homologous
recombination (HR) [33,34]. As both processes, TLS and HR,
act mainly in the S phase of the cell cycle, S phase arrest in
XP30RO cells after treatment with DOX was expected. In-
stead, G2/M arrest was observed, with high levels of
cH2AX-labeled cells. If this is so, pol eta-induced protec-
tion against DOX treatments would not involve HR, but a
third undetermined pathway.It is believed that pol eta could be necessary to allow
late replication of sequences with speciﬁc structures that
may be produced spontaneously or in the presence of
DNA lesions, such as stalled replication forks, G4-tetraplex
sequences [35] or fragile site sequences [36]. In fact, many
DNA polymerases have either cooperative or redundant
roles and participate in more than one cellular process.
For example, Auclair and colleagues showed that func-
tional DNA polymerase eta is important for GGR during
the S phase [37], and other authors have also proposed that
DNA polymerase eta might play a role in NER [38,39].
Whether this polymerase is required for the NER repair
of DOX-induced DNA damage is an issue that requires fur-
ther study. Preliminary work indicated that silencing of pol
eta expression in XP-A cells (by shRNA knock down) do not
change the levels of cell killing by DOX-treatment (Fig. 1S,
Supplementary Data), indicating that pol eta and XPA
could, in fact, operate in the same pathway. That would
indicate that pol eta could be involved in the NER synthesis
step. This, however, should be considered carefully, as
these cells also did not had increased killing by UV-damage
(Fig. 1S, C), and thus the reduction of XPV proteins in the
cells could not be enough for an observable effect.
Finally, LY294002, an inhibitor of PI3Ks and PIKKs, was
found to enhance DOX cytotoxic effects only in the DNA re-
pair deﬁcient cell lines, XP12BE and XP30RO (Figs. 4 and 5).
Some of the kinases inhibited by LY, viz., ATM, ATR and
DNA-PKcs, play important roles in DSB signaling and repair
[21,22], and this is in agreement with the observation that
the number of cHAX-labeled cells increases in DOX-trea-
ted cells. Together with the synergistic effect of LY in the
cell killing of XP-A and XP-V cells, these results clearly
indicate that these kinases signal and help to process DSBs,
which are probably induced by the presence of lesions not
repaired by NER or pol eta. The lack of speciﬁcity of LY,
however, do not provide a direct information on the type
of kinase(s) related to the repair of such lesions, when in-
duced by DOX-treatment. The involvement of DNA-PKcs
M.C.S. Moraes et al. / Cancer Letters 314 (2012) 108–118 117in DSB repair by NHEJ, thereby implying the possible
participation of this pathway in the repair of DOX-induced
DSBs, is in accordance with previous work [2]. The activa-
tion of ATM in DOX-treated human lymphoblastoid cells
have also been reported, indicating that this kinase is also
involved in the cell responses triggered by this drug [27]. It
is tempting to consider the possibility of a mechanistic link
among these proteins, in a direct cross-talk between differ-
ent repair pathways. Even though currently the existence
of such a link is no more than speculation, it would be
interesting to investigate this further.
Taken together, the results shed light onto how DOX-in-
ducedDNA damages are repaired. In Fig. 8, amodel summa-
rizing the data and identifying possible pathways involved
in the processing of the different types of lesions induced by
DOX is presented. This model facilitates the identiﬁcation
of the novel potential targets that can be clinically tested
with DOX, so as to improve the outcome of chemotherapeu-
tic treatment with this drug. Corroborating our model, re-
cent data indicate that tumors from a BRCA-defective
background, that should be partially deﬁcient in recombi-
nation of DSB, appear to be more sensitive to pegylated
liposomal doxorubicin [40]. Besides increasing the quality
in the treatment received by thousands of patients world-
wide, it is possible that in a not so distant future, the repair
capacity of tumor cells will be addressed before the begin-
ning of a treatment, and thus patients with impaired capac-
ity will bemore apt candidates for chemotherapy with DOX
than patients with enhanced capacity.Acknowledgements
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